Positive News SentimentPositive NewsNASDAQ:ABVC ABVC BioPharma (ABVC) Stock Price, News & Analysis $1.08 +0.01 (+0.93%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.09 +0.01 (+0.93%) As of 05/14/2026 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ABVC BioPharma Stock (NASDAQ:ABVC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ABVC BioPharma alerts:Sign Up Key Stats Today's Range$1.04▼$1.0950-Day Range$0.91▼$1.4652-Week Range$0.88▼$5.48Volume76,387 shsAverage Volume74,474 shsMarket Capitalization$27.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens. The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy. Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.AI Generated. May Contain Errors. Read More ABVC BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreABVC MarketRank™: ABVC BioPharma scored higher than 24% of companies evaluated by MarketBeat, and ranked 777th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingABVC BioPharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageABVC BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about ABVC BioPharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of ABVC BioPharma is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ABVC BioPharma is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioABVC BioPharma has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ABVC BioPharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of ABVC BioPharma has been sold short.Short Interest Ratio / Days to CoverABVC BioPharma has a short interest ratio ("days to cover") of 3.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABVC BioPharma has recently decreased by 12.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABVC BioPharma does not currently pay a dividend.Dividend GrowthABVC BioPharma does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentABVC BioPharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ABVC BioPharma this week, compared to 1 article on an average week.Search Interest1 people have searched for ABVC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added ABVC BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABVC BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of ABVC BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.38% of the stock of ABVC BioPharma is held by institutions.Read more about ABVC BioPharma's insider trading history. Receive ABVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABVC Stock News HeadlinesABVC BioPharma Reports 2025 Form 10-KMarch 4, 2026 | finance.yahoo.comABVC BioPharma Provides Corporate and Structural UpdateFebruary 24, 2026 | finance.yahoo.comThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing. | American Alternative (Ad)ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United StatesDecember 2, 2025 | finance.yahoo.comABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods ...November 26, 2025 | finance.yahoo.comABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 MillionNovember 18, 2025 | finance.yahoo.comABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025November 3, 2025 | theglobeandmail.comABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950October 31, 2025 | finance.yahoo.comSee More Headlines ABVC Stock Analysis - Frequently Asked Questions How have ABVC shares performed this year? ABVC BioPharma's stock was trading at $2.13 at the beginning of the year. Since then, ABVC shares have decreased by 49.3% and is now trading at $1.08. How were ABVC BioPharma's earnings last quarter? ABVC BioPharma, Inc. (NASDAQ:ABVC) announced its earnings results on Tuesday, March, 3rd. The company reported ($0.11) EPS for the quarter. When did ABVC BioPharma's stock split? Shares of ABVC BioPharma reverse split on the morning of Tuesday, July 25th 2023.The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did ABVC BioPharma IPO? ABVC BioPharma (ABVC) raised $7 million in an IPO on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share. Who are ABVC BioPharma's major shareholders? Top institutional shareholders of ABVC BioPharma include Renaissance Technologies LLC (0.37%). How do I buy shares of ABVC BioPharma? Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ABVC BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS). Company Calendar Last Earnings3/03/2026Today5/15/2026Next Earnings (Estimated)5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ABVC's financial health is in the Yellow zone, according to TradeSmith. ABVC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVC CIK1173313 Webwww.abvcpharma.com Phone(510)-668-0881FaxN/AEmployees30Year Founded2002Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.91 million Net MarginsN/A Pretax Margin-768.55% Return on Equity-65.11% Return on Assets-40.13% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$510 thousand Price / Sales53.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book2.08Miscellaneous Outstanding Shares25,440,000Free Float20,606,000Market Cap$27.48 million OptionableNot Optionable Beta0.42 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ABVC) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
